<div id="readability-page-1"><p>Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) has been given a consensus recommendation of &#34;Moderate Buy&#34; by the nine research firms that are  covering the stock, MarketBeat.com reports. One investment analyst  has rated the stock with a hold rating and eight have given a buy rating to  the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $23.3333.</p><div><p><span></span><span>Get <strong>Zevra Therapeutics</strong> alerts:</span></p></div><p>A number of equities research analysts recently commented on ZVRA shares. Guggenheim increased their price objective on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the company a &#34;buy&#34; rating in a research note on Friday. Wall Street Zen raised shares of Zevra Therapeutics from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Saturday, April 11th. BTIG Research began coverage on shares of Zevra Therapeutics in a research note on Monday, March 16th. They set a &#34;buy&#34; rating and a $23.00 price target on the stock. Finally, Weiss Ratings raised shares of Zevra Therapeutics from a &#34;hold (c+)&#34; rating to a &#34;buy (b-)&#34; rating in a research note on Friday.</p><p><b>View Our Latest Stock Analysis on ZVRA</b></p><h2>Zevra Therapeutics Stock Performance</h2><p>Shares of NASDAQ ZVRA opened at $11.13 on Monday. The stock has a market cap of $658.01 million, a price-to-earnings ratio of 5.59 and a beta of 0.88. Zevra Therapeutics has a 52 week low of $7.16 and a 52 week high of $13.16. The company's 50-day moving average price is $9.73 and its 200 day moving average price is $9.25. </p><p>Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.18 EPS for the quarter, beating analysts' consensus estimates of $0.06 by $0.12. The firm had revenue of $36.22 million for the quarter, compared to analysts' expectations of $31.96 million. Zevra Therapeutics had a net margin of 101.58% and a return on equity of 51.49%.  As a group, research analysts expect that  Zevra Therapeutics will post 0.52 earnings per share for the current year. </p><h2>Institutional Investors Weigh In On Zevra Therapeutics</h2><p>Hedge funds have recently modified their holdings of the company. CWM LLC boosted its stake in shares of  Zevra Therapeutics by 399.5% during the 3rd quarter. CWM LLC now owns 2,872 shares of the company's stock worth $27,000 after purchasing an additional 2,297 shares during the last quarter.  Gunpowder Capital Management LLC dba Oliver Wealth Management acquired a new stake in shares of  Zevra Therapeutics during the 4th quarter worth about $53,000.  Russell Investments Group Ltd. boosted its stake in shares of  Zevra Therapeutics by 235.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company's stock worth $61,000 after purchasing an additional 4,475 shares during the last quarter.  Tower Research Capital LLC TRC boosted its stake in shares of  Zevra Therapeutics by 617.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company's stock worth $88,000 after purchasing an additional 8,552 shares during the last quarter.  Finally, Creative Planning acquired a new stake in shares of  Zevra Therapeutics during the 2nd quarter worth about $92,000. 35.03% of the stock is owned by institutional investors and hedge funds. </p><h2>Key Zevra Therapeutics News</h2><p>Here are the key news stories impacting Zevra Therapeutics this week:</p><ul>   <li><span>Positive Sentiment: </span>HC Wainwright raised Zevra’s Q2 2026 EPS estimate to $0.06 from $0.03, signaling better near-term earnings expectations.</li>   <li><span>Positive Sentiment: </span>The firm also increased Q3 2026 EPS estimates to $0.11 from $0.08 and Q4 2026 EPS estimates to $0.17 from $0.12, reflecting stronger expected profitability.</li>   <li><span>Positive Sentiment: </span>HC Wainwright lifted its FY2027 and FY2030 earnings forecasts, suggesting confidence in Zevra’s long-term growth trajectory.</li>   <li><span>Neutral Sentiment: </span>One analyst lowered FY2028 and FY2029 estimates slightly, but the changes were modest and did not offset the broader upward revisions. <i></i><span>Zevra Therapeutics stock page</span></li> </ul><h2>Zevra Therapeutics Company Profile</h2> (Get Free Report)<p>Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Zevra Therapeutics</li><li>Beyond NVIDIA: Picks-and-Shovels AI Plays with Strong Momentum</li><li>Quantum Earnings Season Is Ramping Up—What to Watch From 2 Major Players</li><li>Flutter Sees Post-Earnings Boost as FanDuel Shows Signs of Recovery</li><li>3 Healthcare Stocks Set to Benefit From the One Big Beautiful Bill</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WlZSQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WlZSQQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Zevra Therapeutics Right Now?</h2><p>Before you consider Zevra Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zevra Therapeutics wasn't on the list.</p><p>While Zevra Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ZVRA

ARKG

LABU

SBIO

<p>Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has received a consensus rating of "Moderate Buy" from nine research firms. Analysts have set an average price target of $23.33, with one hold and eight buy ratings. Recent upgrades include Guggenheim raising its target to $25 and BTIG initiating coverage with a $23 target. The stock opened at $11.13, with a market cap of $658.01 million. Zevra reported $0.18 EPS for Q2, exceeding estimates, and has a net margin of 101.58%. Institutional investors hold 35.03% of the stock, reflecting growing interest.</p>

Market Beat

Zevra Therapeutics

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

ALPS Medical Breakthrough

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

K Wave Media

Cushman & Wakefield

SEAPEAK LLC 9% CUM RED PERP PREF UNITS SER A

Nano Labs

Annaly Capital Mgmt

Mag Mile Capital, Inc.

Sun Capital Management Corp.

Russell Inv Global Equity ETF

Russell Investment Management LLC

Trinity Capital

TCP Capital

GH Research

Creative Realities

CREATIVE GLOBAL

Capital Asset Planning, Inc.

NVIDIA

K WAVE MEDIA LTD C/WTS 14/05/2030(TO PUR COM)

SEAPEAK LLC 8.5% CUM RED PERP PFD UNTS FXD FLT SER B

ANNALY CAPITAL MANAGEMENT INC 6.95% FXD FLTG CUM RED PFD SR F 30/09/22

ANNALY CAPITAL MANAGEMENT INC 8.875 CUM PREF SER J

ANNALY CAPITAL MANAGEMENT INC 6.750% FXD TO FTG RATE CUM RED PRF SR I

ANNALY CAPITAL MANAGEMENT INC 6.50 CUM RED PFD STK FIX FLT SER G USD25

Trinity Capital Pref Share TRINL 7 01/16/25

TRINITY CAPITAL INC 7.875% NTS 30/09/2029

TRINITY CAPITAL INC 7.875% NOTES DUE 2029

NVIDIA Corporation

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of "Moderate Buy" by Brokerages